DarioHealth (DRIO) Q4 2024 earnings summary

Executive summary

• Achieved a transformational year, evolving into a leading AI-powered digital health platform supporting five chronic conditions and integrating the Twill acquisition.

• Full-year 2024 revenue rose 32.9% to $27.0M, driven by B2B2C channel growth and Twill acquisition integration.

• Recurring B2B2C revenues increased 300% year-over-year to $20.0M; client base grew to 83, with 36 new wins.

• Gross margins in B2B2C exceeded 80% for the past three quarters, supporting a path to sustainable profitability.

• Integration of AI tools and post-merger consolidation expected to reduce operating expenses by an additional 20% by Q4 2025.

Financial highlights

• 2024 total revenue reached $27 million, a 32.9% increase from $20.4 million in 2023.

• Q4 2024 revenue was $7.6M, up 110% year-over-year and 2.4% sequentially; B2B2C recurring revenue reached $5.6M, up 398% year-over-year.

• Full-year 2024 gross profit was $13.3M, up 122% from 2023; pro-forma gross profit margin for 2024 was 67.7%.

• Pro forma gross profit margin increased from 51% to 72%; B2B2C gross margin was about 80% for the last three quarters.

• Full-year 2024 net loss was $42.7M, improved from $59.4M in 2023; adjusted net loss was $18.8M, down from $34.6M.

Outlook and guidance

• Targeting 50% net client growth in 2025, with a focus on expanding across employers, health plans, and pharma partnerships.

• On track for operational cash flow break-even by end of 2025, supported by cost reductions and business momentum.

• Additional 20% reduction in operating expenses anticipated by Q4 2025 through AI and consolidation.

• GLP-1 solutions expected to double in number of accounts and become a larger revenue contributor.

• No formal revenue guidance for 2025, but aiming for 35% growth rate across all channels.